ORCID Profile
0000-0002-6427-6140
Current Organisation
China University of Mining and Technology
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 12-10-2022
DOI: 10.1002/HEP.32811
Publisher: Springer Science and Business Media LLC
Date: 06-07-2021
DOI: 10.1007/S10620-021-07140-W
Abstract: Alcoholic hepatitis is a common condition with high mortality. This study aimed to firstly describe the presentation, treatment, and short- and long-term outcomes of an Australian cohort of patients admitted to hospital with alcoholic hepatitis and secondly to validate existing prognostic models. This is a retrospective study of consecutive patients admitted with alcoholic hepatitis to a major academic liver center in Melbourne, Australia, between January 1, 2010, and December 31, 2019. Cases were identified through appropriate International Classification of Diseases version 10 coding as well as review of non-coded patients with compatible biochemistry. Baseline demographic data, alcohol consumption, laboratory values, treatment, and outcomes at 30 days, 90 days, and 12 months post-diagnosis were collected from electronic medical records. Mortality data were extracted from an independent state government death registry. In total, 126 patients (72 males [57%], median age 51 years) were included in the final analysis. Ninety-five (75%) were cirrhotic at diagnosis, 81 (64%) met criteria for severe alcoholic hepatitis, and 41 (33%) had an infection during their index admission. 54% of eligible patients were treated with corticosteroids. 30-day and 12-month mortality rates were 8.7% and 27.1%, respectively, with hepatic encephalopathy (hazard ratio 5.45) and neutrophil-to-lymphocyte ratio (hazard ratio 1.09) independent markers for 12-month mortality on Cox regression analysis. Glasgow alcoholic hepatitis score outperformed other major prognostic models for short-term mortality. The 12-month mortality rate of 27% following alcoholic hepatitis is lower than previously reported studies, with hepatic encephalopathy and neutrophil-to-lymphocyte ratio predictive of long-term outcome.
Publisher: Wiley
Date: 23-08-2021
DOI: 10.1111/APT.16539
Abstract: This article is linked to Forrest et al and Forrest & Goldin papers. To view these articles, visit 0.1111/apt.16157 and 0.1111/apt.16559
Publisher: Wiley
Date: 12-08-2023
DOI: 10.1111/JGH.16314
Abstract: Non‐alcoholic fatty liver disease (NAFLD) is the most prevalent liver condition globally. The aim of this study was to evaluate the change in age‐ and sex‐standardized prevalence of NAFLD in regional Victoria over a 15‐year period and explore the underlying factors associated with differences over time. Repeated comparative cross‐sectional studies in four towns in regional Victoria, Australia. In iduals randomly selected from households from residential address lists from local government organizations in 2001–2003 (CrossRoads I [CR1]) and 2016–2018 (CrossRoads II [CR2]) with 1040 (99%) and 704 (94%) participants from CR1 and CR2 having complete data for analysis. Primary outcome was change in prevalence estimates of NAFLD (defined by a fatty liver index ≥ 60 in the absence of excess alcohol and viral hepatitis) between 2003 and 2018. Crude prevalence of NAFLD increased from 32.7% to 38.8% ( P 0.01), while age‐standardized/sex‐standardized prevalence increased from 32.4% to 35.4% ( P 0.01). Concurrently, prevalence of obesity defined by BMI and elevated waist circumference increased 28% and 25%, respectively. Women had a greater increase in the prevalence of NAFLD than men, in parallel with increasing prevalence of obesity. Proportion of participants consuming takeaway food greater than once weekly increased significantly over time. Up to 60% of NAFLD patients require additional tests for assessment of significant fibrosis. Crude and age‐standardized/sex‐standardized prevalence of NAFLD have both increased significantly over the last 15 years, particularly among women, in association with a parallel rise in the prevalence of obesity.
Publisher: Springer Science and Business Media LLC
Date: 03-06-2019
Publisher: Wiley
Date: 03-10-2022
DOI: 10.1111/IMJ.15932
Abstract: The 30‐day hospital readmission rate in cirrhotic patients has been demonstrated to be up to 40% in international studies, but is not well studied in Australia. The aim of the current study was to report on the rate and cause of 30‐day hospital readmission from a single liver transplant referral centre, including a cost analysis of readmissions. This was a retrospective study of consecutive cirrhotic patients admitted to a liver transplant centre in Victoria, Australia, between 1 January 2019 and 31 December 2019. Cases were identified through International Classification of Diseases , Tenth Revision , 10 coding for cirrhosis and its complications. Baseline demographic data, liver‐related complications and unrelated extra‐hepatic comorbidities, laboratory values and prognostic scores were collected from the electronic medical record. One hundred seventy‐nine (63% men median age at index admission, 59 years) patients who were admitted 427 times during the study period were included in the final analysis. The 30‐day hospital readmission rate was 46%, with the majority of readmissions attributable to fluid overload (29%), miscellaneous reasons (27%) and infection (20%). One fifth of readmissions were considered preventable. History of variceal haemorrhage was found to be an independent predictor of 30‐day hospital readmission. The annual cost of readmission is over AU$2.7 million and the median cost of hospital readmission was about AU$9000. The 30‐day hospital readmission rate of 46% is higher than previously reported and almost half of cases were caused by either fluid overload or infection.
Publisher: Elsevier BV
Date: 10-2023
Location: No location found
No related grants have been discovered for Karl Vaz.